Delivery system for budesonide based on lipid-DNA

Yun Liu, I. Sophie T. Bos, Tjitske A. Oenema, Herman Meurs, Harm Maarsingh, Anna K. H. Hirsch*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Scopus)

Abstract

Budesonide is a hydrophobic glucocorticoid with high anti-inflammatory activity for the treatment of asthma, inflammatory bowel disease and rheumatoid arthritis. A micellar drug-delivery system based on lipid-DNA may provide a strategy to maximize its drug efficacy and reduce adverse effects. In this work, we report the use of lipid-DNAA (UU11mer), featuring two hydrophobic alkyl chains and forming micelles at a comparatively low critical micelle concentration, to render budesonide water-soluble with a high loading capacity (LC). The inhibition of interleukin-8 (IL-8) release shows that the new delivery system retains the inhibitory activity in cell based assays. In conclusion, this research provides a novel approach to formulate and administer budesonide in a non-invasive manner, which dramatically improves its water-solubility while retaining its bioavailability.

Original languageEnglish
Pages (from-to)123-127
Number of pages5
JournalEuropean Journal of Pharmaceutics and Biopharmaceutics
Volume130
DOIs
Publication statusPublished - Sep-2018

Keywords

  • Drug delivery
  • Anti-inflammatory
  • Budesonide
  • Lipid-DNA
  • Solubility
  • AIRWAY SMOOTH-MUSCLE
  • DRUG-DELIVERY
  • RHEUMATOID-ARTHRITIS
  • ULCERATIVE-COLITIS
  • POLYMERIC MICELLES
  • CROHNS-DISEASE
  • ASTHMA
  • THERAPY
  • PHARMACOKINETICS
  • CORTICOSTEROIDS

Cite this